Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus